Novocure Shares Rise After FDA Approves Optune Lua Cancer Treatment
Shares of Novocure were trading higher in Tuesday's late session after the company said that the Food and Drug Administration had approved Optune Lua, its wearable treatment for certain types of lung cancer. The stock rose 13% to trade at $20.20, and ended the day's regular session with an 11% gain, closing at $17.78.